NKTR · Nektar Therapeutics

Nektar Therapeutics reported its first quarter 2026 financial results, highlighting a reduced net loss of $44.9 million compared to $50.9 million in the same period last year. The improvement was primarily driven by a significant decrease in general and administrative expenses, which fell to $13.4 million from $24.3 million, largely due to lower legal expenses. Research and development expenses increased to $35.7 million from $30.5 million, reflecting heightened activities to support the Phase 3 program for rezpegaldesleukin in atopic dermatitis. Revenue remained relatively flat at $10.9 million, consisting entirely of non-cash royalty revenue. The company's cash and marketable securities position strengthened substantially to $731.6 million as of March 31, 2026, up from $245.8 million at year-end 2025, bolstered by a $460 million public offering in February. Additionally, a subsequent secondary offering in April 2026 raised approximately $351 million in net proceeds, further enhancing liquidity. Management emphasized that 2026 is a defining year, with the Phase 3 ZENITH-AD program for atopic dermatitis set to initiate by July and an End-of-Phase 2 meeting with the FDA for alopecia areata expected in the current quarter. The company also highlighted positive longer-term treatment data for rezpegaldesleukin, reinforcing its potential as a novel Treg mechanism for autoimmune diseases. Overall, the results reflect a company transitioning into late-stage development with a strengthened balance sheet and focused pipeline execution.